Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine

Muramatsu, Hiromi and Lam, Kieu and Bajusz, Csaba and Laczkó, Dorottya and Karikó, Katalin (2022) Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. MOLECULAR THERAPY, 30 (5). pp. 1941-1951. ISSN 1525-0016

Preview

Text 1-s2.0-S1525001622000843-main.pdf Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

Lipid nanoparticle (LNP)-formulated nucleoside-modified mRNA vaccines have proven to be very successful in the fight against the coronavirus disease 2019 (COVID-19) pandemic. They are effective, safe, and can be produced in large quantities. However, the long-term storage of mRNA-LNP vaccines without freezing is still a challenge. Here, we demonstrate that nucleoside-modified mRNA-LNPs can be lyophilized, and the physicochemical properties of the lyophilized material do not significantly change for 12 weeks after storage at room temperature and for at least 24 weeks after storage at 4??C. Importantly, we show in comparative mouse studies that lyophilized firefly luciferase-encoding mRNA-LNPs maintain their high expression, and no decrease in the immunogenicity of a lyophilized influenza virus hemagglutinin-encoding mRNALNP vaccine was observed after 12 weeks of storage at room temperature or for at least 24 weeks after storage at 4??C. Our studies offer a potential solution to overcome the longterm storage-related limitations of nucleoside-modified

Actions (login required)

Edit Item